{"id":475571,"date":"2020-03-23T13:20:02","date_gmt":"2020-03-23T13:20:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=475571"},"modified":"2020-03-23T13:20:02","modified_gmt":"2020-03-23T13:20:02","slug":"chronic-lower-back-pain-clbp-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chronic-lower-back-pain-clbp-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_475571.html","title":{"rendered":"Chronic Lower Back Pain (CLBP) Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight"},"content":{"rendered":"
\"Chronic<\/a><\/div>\n

DelveInsight has launched a new report on Chronic Lower Back Pain (CLBP)<\/span> Market Insights, Epidemiology and Market Forecast-2030<\/strong><\/p>\n

DelveInsight’s ‘<\/span>Chronic Lower Back Pain (CLBP)- Market Insights, Epidemiology and Market Forecast-2028<\/span> report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of CLBP in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/span><\/p>\n

Chronic low back pain (CLBP)<\/strong> is a pain that persists for 12 weeks or longer, even after an initial injury or underlying cause of acute low back pain has been treated. Low back pain is widespread, and at one point, everyone might have faced it; however, the exact cause of lower back pain is unknown. Lower back pain that is long-term (for more than 3 months) is called chronic low back pain, this condition might originate from an injury, disease, or stress on different structures of the body, and may vary significantly and felt as bone pain, nerve pain, or muscle pain.<\/p>\n

 <\/p>\n

\"\"<\/p>\n

 <\/p>\n

Request for :- <\/strong>Chronic Lower Back Pain free sample page<\/a><\/p>\n

 <\/strong><\/p>\n

Chronic Lower Back Pain Epidemiology  <\/strong><\/p>\n

The CLBP <\/span>epidemiology division provides insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight’s report also provides the diagnosed patient pool and their trends along with assumptions undertaken.<\/p>\n

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalent Population<\/span>, Gender-Specific Prevalent Population<\/span>, Age-Specific Prevalent Population<\/span>, Severity-Specific Prevalent Population<\/span>, Number of CLBP Patients on Prescription Medications by different Class <\/span>and Number of CLBP Patients on Opioids by low dose, high dose, and overdose<\/span>] scenario of CLBP in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2028.<\/p>\n

As per DelveInsight’s analysis, a higher percentage of diagnosed prevalence was observed for females, in comparison to males, in all the 7MM countries, except Japan, wherein males occupy a larger patient pool than females. According to DelveInsight’s estimations, the total prevalent population<\/span> of CLBP in the 7MM was observed to be 73,802,461<\/span> in 2017, which is expected to increase during the study period i.e.<\/em> 2017-2028. Furthermore, the total diagnosed prevalent<\/span> population of CLBP in the 7MM was assessed to be 44,281,476 <\/span>in 2017<\/p>\n

Some of the Report Key facts:- <\/strong><\/p>\n

    \n
  1. As per DelveInsight’s analysis, a higher percentage of diagnosed prevalence was observed for females in comparison to males, in all the 7MM countries, except Japan, wherein males occupy a larger patient pool than females.<\/li>\n
  2. According to DelveInsight’s estimations, the total prevalent population of CLBP in the 7MM was observed to be73,802,461<\/strong> in 2017, which is expected to increaseduring the study period,i.e., 2017–2030.<\/li>\n
  3. Furthermore, the total diagnosed prevalent population of CLBPin the 7MM was assessed to be 44,281,476 <\/strong>in 2017.<\/li>\n<\/ol>\n

    Report Key Benefits<\/strong><\/p>\n